Interim report January-March 2011
(Thomson Reuters ONE) -
Period January - March
· The Group's net sales for the period were SEK 134 (131) million. Adjusted for
the divested OTC products, sales were SEK 112 million for the previous year.
· EBITDA for the period amounted to SEK 31 (18) million. Adjusted for the
divested OTC products, EBITDA for the previous year was SEK 10 million.
· Operating profit totalled SEK 25 (11) million.
· Profit/loss after tax for the period was SEK 18 (-3) million.
· Earnings per share after tax, before and after dilution, for the period were
SEK 0.05 (-0.01).
Significant events during the period
· BioPhausia acquired renewed confidence as the main supplier of parallel-
imported pharmaceuticals to Apoteksgruppen.
Significant events after the period
· On 11 April Medivir AB submitted a public takeover bid for all shares and
listed warrants in BioPhausia.
Interim report January-March 2011:
http://hugin.info/130049/R/1516044/452352.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioPhausia AB via Thomson Reuters ONE
[HUG#1516044]
Unternehmensinformation / Kurzprofil:
Datum: 16.05.2011 - 09:47 Uhr
Sprache: Deutsch
News-ID 54691
Anzahl Zeichen: 1602
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 212 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Interim report January-March 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
BioPhausia AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
